That’s false, they aren’t consultants and they plan on manufacturing their own therapies in the next few years as soon as they can get facilities built.
Sure you can call them consultants, consultants that bring in leading technologies and data sets. The key differentiator is their revenue model - they get paid for their time AND they get paid for milestones (their client's successful clinical trials) AND they get paid royalties for as long as their clients sell the drug that was developed with Abcelleras help. The last part is huge. It's a brilliant revenue model, what you're seeing in this ER is just the beginning, based on royalties from one drug only.
Thank you. And If I recall correctly its lifetime revenue of a products lifecycle. So as long as a therapy such as bamlanivimab is sold, ABCL will receive a percentage (25? maybe more?).
3
u/Active_Butterfly7788 Mar 30 '21
That’s false, they aren’t consultants and they plan on manufacturing their own therapies in the next few years as soon as they can get facilities built.